title: Combined prostaglandin and nitric oxide inhibition produces anatomic remodeling and closure of the ductus arteriosus in the premature newborn baboon.
abstract: After birth, the full-term ductus arteriosus actively constricts and undergoes extensive histologic changes that prevent subsequent reopening. These changes are thought to occur only if a region of intense hypoxia develops within the ductus wall after the initial active constriction. In preterm infants, indomethacin-induced constriction of the ductus is often transient and is followed by reopening. Prostaglandins and nitric oxide both play a role in inhibiting ductus closure in vitro. We hypothesized that combined inhibition of both prostaglandin and nitric oxide production (with indomethacin and N-nitro-L-arginine (L-NA), respectively) may be required to produce the degree of functional closure that is needed to cause intense hypoxia. We used preterm (0.67 gestation) newborn baboons that were mechanically ventilated for 6 d: 6 received indomethacin alone, 7 received indomethacin plus L-NA, and 16 received no treatment (control). Just before necropsy, only 25% of control ductus and 33% of indomethacin-treated ductus were closed on Doppler examination; in contrast, 100% of the indomethacin-plus-L-NA-treated ductus were closed. Control and indomethacin-treated baboons developed negligible-to-mild ductus hypoxia (EF5 technique). Similarly, there was minimal evidence of ductus remodeling. In contrast, indomethacin-plus-L-NA-treated baboons developed intense hypoxia in regions where the ductus was most constricted. The hypoxic muscle strongly expressed vascular endothelial growth factor, and proliferating luminal endothelial cells filled and occluded the lumen. In addition, cells in the most hypoxic regions were undergoing DNA fragmentation. In conclusion, preterm newborns are capable of remodeling their ductus, just like the full-term newborn, if they can reduce their luminal blood flow to a point that produces intense ductus wall hypoxia. Combined prostaglandin and nitric oxide inhibition may be necessary to produce permanent closure of the ductus and prevent reopening in preterm infants.
authors.affiliation: Cardiovascular Research Institute, University of California San Francisco, CA 94143-0544, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Seidner
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Chen
authors.forename: P R
authors.initials: PR
authors.lastname: Oprysko
authors.forename: F
authors.initials: F
authors.lastname: Mauray
authors.forename: M M
authors.initials: MM
authors.lastname: Tse
authors.forename: E
authors.initials: E
authors.lastname: Lin
authors.forename: C
authors.initials: C
authors.lastname: Koch
authors.forename: R I
authors.initials: RI
authors.lastname: Clyman
mesh_terms: D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D006690:Bisbenzimidazole / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000494:pharmacology; D053938:DNA Fragmentation; D004373:Ductus Arteriosus / Q000033:anatomy & histology* / Q000187:drug effects / Q000502:physiology; D016228:Endothelial Growth Factors / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017341:Etanidazole / Q000031:analogs & derivatives* / Q000378:metabolism; D005333:Fetus / Q000502:physiology; D005456:Fluorescent Dyes; D006845:Hydrocarbons, Fluorinated / Q000378:metabolism; D000860:Hypoxia / Q000378:metabolism; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007202:Indicators and Reagents / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D008222:Lymphokines / Q000378:metabolism; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D019335:Nitroarginine / Q000494:pharmacology; D010215:Papio / Q000502:physiology*; D011453:Prostaglandins / Q000378:metabolism*; D012143:Respiratory Physiological Phenomena / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005466:Fluorocarbons
chemical_list: D006690:Bisbenzimidazole; D002317:Cardiovascular Agents; D016228:Endothelial Growth Factors; D004791:Enzyme Inhibitors; D017341:Etanidazole; D005456:Fluorescent Dyes; D006845:Hydrocarbons, Fluorinated; D007202:Indicators and Reagents; D007213:Indomethacin; D008222:Lymphokines; D009569:Nitric Oxide; D019335:Nitroarginine; D011453:Prostaglandins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C096011:2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; D005466:Fluorocarbons